BioVaxys Secures US Patent for Innovative Vaccine Delivery
Company Announcements

BioVaxys Secures US Patent for Innovative Vaccine Delivery

Story Highlights

BioVaxys Technology (TSE:BIOV) has released an update.

BioVaxys Technology Corp. has been granted a U.S. patent for a novel low-dose vaccine delivery system that enhances antibody immune response, with promising applications in various diseases. The proprietary DPX™ technology allows for a potent and sustained immune response, which has shown encouraging results in clinical studies for RSV, with potential for other diseases.

For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBioVaxys Joins US Vaccine Development Consortium
TipRanks Canadian Auto-Generated NewsdeskBioVaxys Advances in Drug Delivery Market
TipRanks Canadian Auto-Generated NewsdeskBioVaxys to Present at Emerging Growth Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App